Insider Trading Activity Aclaris Therapeutics (NASDAQ:ACRS) – Insider Bought 10,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Aclaris Therapeutics (NASDAQ:ACRS)

Neal Walker , Insider of Aclaris Therapeutics (NASDAQ:ACRS) reportedly Bought 10,000 shares of the company’s stock at an average price of 16.75 for a total transaction amount of $167,500.00 SEC Form

Insider Trading History For Aclaris Therapeutics (NASDAQ:ACRS)

  • On 10/7/2015 Vivo Ventures Vii, Llc, Major Shareholder, bought 13,352 with an average share price of $11.00 per share and the total transaction amounting to $146,872.00.
  • On 10/8/2015 Ra Capital Management, Llc, Major Shareholder, bought 2,237,130 with an average share price of $10.86 per share and the total transaction amounting to $24,295,231.80.
  • On 10/13/2015 Sofinnova Venture Partners Vii, Major Shareholder, bought 409,090 with an average share price of $11.00 per share and the total transaction amounting to $4,499,990.00.
  • On 10/13/2015 Fmr Llc, Insider, bought 335,455 with an average share price of $11.00 per share and the total transaction amounting to $3,690,005.00.
  • On 10/13/2015 Albert Cha, Director, bought 454,545 with an average share price of $11.00 per share and the total transaction amounting to $4,999,995.00.
  • On 10/14/2015 Ra Capital Management, Llc, Major Shareholder, bought 42,813 with an average share price of $14.06 per share and the total transaction amounting to $601,950.78.
  • On 10/21/2015 Ra Capital Management, Llc, Major Shareholder, bought 34,999 with an average share price of $14.89 per share and the total transaction amounting to $521,135.11.

    • Analyst Ratings History For Aclaris Therapeutics (NASDAQ:ACRS)

    • On 7/31/2017 Jefferies Group Reiterated Rating Buy with a price target of $36.00
    • On 9/8/2017 JMP Securities Reiterated Rating Outperform with a price target of $39.00
    • On 2/8/2018 Guggenheim Initiated Coverage of rating Buy to Buy with a price target of $53.00
    • On 3/28/2018 Leerink Swann Lower Price Target of rating Outperform to Outperform with a price target of $54.00 to $52.00
    • On 4/6/2018 Cantor Fitzgerald Set Price Target of rating Buy with a price target of $50.00

    Recent Trading Activity for Aclaris Therapeutics (NASDAQ:ACRS)
    Shares of Aclaris Therapeutics closed the previous trading session at 16.56 up +0.10 0.61% with 17.40999984741211 shares trading hands.